In October 2024, the National Health Commission released Clinical Practice Guidelines for the Obesity Diagnosis and Treatment (2024 Edition), which leads to significant implications for clinical diagnosis and treatment of obesity, and potentially impacts the future trend of metabolic and bariatric surgery. The guidelines reflect a more comprehensive and scientific understanding of obesity as a standalone disease. Based on this understanding, the role of metabolic and bariatric surgery in obesity management will be further strengthened, and homogeneous management of obesity will be more widely implemented in future. With the rapid advancement of anti-obesity medications, future solutions for obesity therapy will involve the combined application of multiple treatment modalities, enhance treatment efficiency and improve patient outcomes. As practitioners in the field of metabolic and bariatric surgery, surgeons will need to pragmatically adapt to the discipline’s evolution, expand their knowledge and skillsets, and upgrade themselves from surgeon to metabolic and bariatric specialists proficient in various obesity treatment approaches.
Key words
obesity /
guideline /
metabolic and bariatric surgery /
trends
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］ 国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发肥胖症诊疗指南(2024年版)的通知［EB/OL］.(2025-09-12)［2024-10-17］. http://www.nhc.gov.cn/yzygj/s7659/202410/ae3948b3fc9444feb2ecd26fb2daa111.shtml.
［2］ 刘洋，李梦伊，张鹏，等. 《肥胖症诊疗指南（2024年版）》减重与代谢手术治疗部分解读［J］. 中国实用外科杂志, 2025, 45(5): 533-537. DOI:10.19538/j.cjps.issn1005-2208.2025.05.12.
［3］ Sharma AM, Kushner RF. A proposed clinical staging system for obesity ［J］. Int J Obes (Lond), 2009, 33(3): 289-295. DOI: 10.1038/ijo.2009.2.
［4］ Guo F, Moellering DR, Garvey WT. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity ［J］. Obesity (Silver Spring), 2014, 22(1): 110-118. DOI:10.1002/oby.20585.
［5］ Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: The American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement ［J］. Endocr Pract, 2017, 23(3): 372-378. DOI: 10.4158/EP161688.PS.
［6］ Soroceanu RP, Timofte DV, Danila R, et al. The impact of bariatric surgery on quality of life in patients with obesity ［J］. J Clin Med, 2023, 12(13): 4225. DOI: 10.3390/jcm12134225.
［7］ Cooper TC, Simmons EB, Webb K, et al. Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery ［J］. Obes Surg, 2015, 25(8): 1474-1481. DOI: 10.1007/s11695-014-1560-z.
［8］ Kanbour S, Ageeb RA, Malik RA, et al. Impact of bodyweight loss on type 2 diabetes remission: A systematic review and Meta-regression analysis of randomised controlled trials ［J］. Lancet Diabetes Endocrinol, 2025, 13(4): 294-306. DOI：10.1016/S2213-8587(24)00346-2.
［9］ Meerasa A, Dash S. Weighing in on type 2 diabetes remission ［J］. Diabetes Care, 2022, 45(1): 28-30. DOI: 10.2337/dci21-0041.
［10］ Miras AD, Perez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): A randomised, double-blind, placebo-controlled trial ［J］. Lancet Diabetes Endocrinol, 2019, 7(7): 549-559. DOI: 10.1016/S2213-8587(19)30157-3.
［11］ Mok J, Adeleke MO, Brown A, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: The BARI-OPTIMISE randomized clinical trial ［J］. JAMA Surg, 2023, 158(10): 1003-1011. DOI: 10.1001/jamasurg.2023.2930.
［12］ Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence ［J］. Obesity (Silver Spring), 2023, 31(5): 1280-1289. DOI:10.1002/oby.23736.
